Vascular endothelial growth factor gene polymorphisms and the risk of renal cell carcinoma: Evidence from eight case-control studies

Mancheng Gong; Wenjing Dong; Zhirong Shi; Shaopeng Qiu; Runqiang Yuan

doi:10.18632/oncotarget.14263

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Vascular endothelial growth factor gene polymorphisms and the risk of renal cell carcinoma: Evidence from eight case-control studies

Mancheng Gong, Wenjing Dong, Zhirong Shi, Shaopeng Qiu and Runqiang Yuan _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:8447-8458. https://doi.org/10.18632/oncotarget.14263

Metrics: PDF 1565 views | HTML 2349 views | ?

Abstract

Mancheng Gong1, Wenjing Dong2, Zhirong Shi3, Shaopeng Qiu4, Runqiang Yuan1

1Department of Urology, Zhongshan Affiliated Hospital of Sun Yat-sen University, Zhongshan, Guangdong 528403, China

2Department of Oncology, Zhongshan Affiliated Hospital of Sun Yat-sen University, Zhongshan, Guangdong 528403, China

3Department of Pharmacy, The Second People’s Hospital of Zhuhai, Zhuhai, Guangdong 519020, China

4Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510080, China

Correspondence to:

Runqiang Yuan, email: [email protected]

Keywords: vascular endothelial growth factor, VEGF, renal cell carcinoma, gene polymorphism, meta-analysis

Received: August 20, 2016 Accepted: December 01, 2016 Published: December 27, 2016

ABSTRACT

Background: Vascular endothelial growth factor (VEGF) protein plays important role in renal cell carcinoma (RCC) development and progression. VEGF gene polymorphisms can alter the protein concentrations and might be associated with renal cell carcinoma risk. However, the results of studies investigating the association between VEGF polymorphisms and renal cell carcinoma risk are inconsistent. Thus, a meta-analysis was performed.

Methods: We selected eligible studies via electronic searches. Only high-quality studies were included based on specific inclusion criteria and the Newcastle-Ottawa Scale (NOS).

Results: Eight studies primarily focusing on seven polymorphisms were included in our meta-analysis. Our results showed dramatically high risks for renal cell carcinoma were found regarding most genetic models and alleles of the +936C/T polymorphism (except CT vs. CC). In addition, significant increased renal cell carcinoma risks were found regarding all genetic models and alleles of the -2578C/A polymorphism. However, no significant associations were found between renal cell carcinoma risk and the +1612G/A, -460T/C, -634G/C, -405G/C or -1154G/A polymorphisms.

Conclusions: Our meta-analysis indicates that the +936C/T and -2578C/A polymorphisms of VEGF are associated with an increased risk for renal cell carcinoma. Additional rigorous analytical studies are needed to confirm our results.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14263

Publication Alerts

Post-Publication Promotion

Research Papers:

Vascular endothelial growth factor gene polymorphisms and the risk of renal cell carcinoma: Evidence from eight case-control studies

Abstract